Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US
Author:
Publisher
Informa UK Limited
Subject
Cancer Research,Oncology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.3109/07357907.2010.496759
Reference17 articles.
1. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
2. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
3. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
4. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Cited by 137 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10
2. Bioinformatics and In Vitro Study Reveal ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells;Computational Biology and Chemistry;2024-08
3. Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists;Histopathology;2024-07-08
4. New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?;Cancers;2024-07-05
5. Multilayered proteomics reveals that JAM‐A promotes breast cancer progression via regulation of amino acid transporter LAT1;Cancer Science;2024-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3